Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 36 points (0.2%) at 17,520 as of Thursday, Nov. 6, 2014, 12:00 PM ET. The NYSE advances/declines ratio sits at 1,530 issues advancing vs. 1,416 declining with 183 unchanged. The Health Services industry currently sits down 0.2% versus the S&P 500, which is up 0.2%. Top gainers within the industry include Envision Healthcare Holdings ( EVHC), up 4.5%, Quest Diagnostics ( DGX), up 2.2%, Agilent Technologies ( A), up 1.9%, Grifols ( GRFS), up 1.9% and Edwards Lifesciences ( EW), up 1.5%. TheStreet would like to highlight 3 stocks pushing the industry higher today: 3. Baxter International ( BAX) is one of the companies pushing the Health Services industry higher today. As of noon trading, Baxter International is up $0.50 (0.7%) to $71.40 on average volume. Thus far, 1.2 million shares of Baxter International exchanged hands as compared to its average daily volume of 2.6 million shares. The stock has ranged in price between $70.66-$71.51 after having opened the day at $71.02 as compared to the previous trading day's close of $70.90. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more. Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney diseases, trauma, and other chronic and acute medical conditions. Baxter International has a market cap of $37.1 billion and is part of the health care sector. Shares are up 1.9% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Baxter International a buy, no analysts rate it a sell, and 9 rate it a hold. TheStreet Ratings rates Baxter International as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Baxter International Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.